TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer

BACKGROUND: Whereas the genomic landscape of endocrine‐resistant breast cancer has been intensely characterized in previously treated cases with local or distant recurrence, comparably little is known about genomic alterations conveying primary non‐responsiveness to endocrine treatment in luminal ea...

Descripción completa

Detalles Bibliográficos
Autores principales: Grote, Isabel, Bartels, Stephan, Kandt, Leonie, Bollmann, Laura, Christgen, Henriette, Gronewold, Malte, Raap, Mieke, Lehmann, Ulrich, Gluz, Oleg, Nitz, Ulrike, Kuemmel, Sherko, zu Eulenburg, Christine, Braun, Michael, Aktas, Bahriye, Grischke, Eva‐Maria, Schumacher, Claudia, Luedtke‐Heckenkamp, Kerstin, Kates, Ronald, Wuerstlein, Rachel, Graeser, Monika, Harbeck, Nadia, Christgen, Matthias, Kreipe, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633262/
https://www.ncbi.nlm.nih.gov/pubmed/34779146
http://dx.doi.org/10.1002/cam4.4376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633262/
https://www.ncbi.nlm.nih.gov/pubmed/34779146
http://dx.doi.org/10.1002/cam4.4376

Ejemplares similares